Immunostaining for proliferation markers Ki67 and PCNA revealed a significant reduction in the number of proliferating PAECs upon A-485 treatment, indicating that EP300 inhibition suppressed PAH-PAEC proliferation (Fig. 2D). This evidence concerns the gene PCNA and pulmonary arterial hypertension.